hrs-8080
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Feb 20, 2024 (NCT06222879)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07229560 | Phase 1 | Nov 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07125950 | Phase 2 | Sep 30, 2025 | Henan Medical University |
| NCT07024173 | Phase 3 | Jul 23, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06679036 | Phase 1/Phase 2 (Phase 2) | Nov 25, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06619873 | Phase 1 | Oct 10, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06555068 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2024 | Hengrui Therapeutics, Inc. |
| NCT06222879 | Phase 1/Phase 2 (Phase 2) | Feb 20, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 5 | 5 | 3 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1